AnaptysBio Inc reports results for the quarter ended March 31 - Earnings Summary

• AnaptysBio Inc ANAB.OQ reported a quarterly adjusted loss of $1.28​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-1.64. The mean expectation of eleven analysts for the quarter was for a loss of $1.25 per share. Wall Street expected results to range from $-1.65 to -70 cents per share.

• Revenue rose 286.8% to $27.77 million from a year ago; analysts expected $15.27 million.

• AnaptysBio Inc's reported EPS for the quarter was a loss of $1.28​.

• The company reported a quarterly loss of $39.33 million.

• AnaptysBio Inc shares had risen by 8.2% this quarter and gained 52.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 6.3% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for AnaptysBio Inc is $36.00

This summary was machine generated from LSEG data May 7 at 11:59 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)